Essentials
• Bleeding complications during congenital heart disease surgery in neonatal age are very common.
• We report the perioperative incidence of acquired von Willebrand syndrome (aVWS) in 12 infants.
• aVWS was detected in 8 out of 12 neonates and infants intraoperatively after cardiopulmonary bypass.
• Ten patients received von Willebrand factor concentrate intraoperatively and tolerated it well.
Summary. Background: Cardiac surgery of the newborn and infant with complex congenital heart disease (CHD) is associated with a high rate of intraoperative bleeding complications. CHD-related anatomic features such as valve stenoses or patent arterial ducts can lead to enhanced shear stress in the blood stream and thus cause acquired von Willebrand syndrome (aVWS). Objective: To evaluate the intraoperative incidence and impact of aVWS after cardiopulmonary bypass (CPB) in neonates and infants with complex CHD. Patients/Methods: We conducted a survey of patients aged < 12 months undergoing complex cardiac surgery in our tertiary referral center. Twelve patients, whose blood samples were analyzed for aVWS before CPB and immediately after discontinuation of CPB on a routine basis, were eligible for the analysis. von Willebrand factor antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo), collagen binding activity (VWF:CB), VWF:multimers and factor VIII activity (FVIII:C) were determined. Results: aVWS was diagnosed by VWF multimer analysis in 10 out of 12 patients (83%) prior to surgery and intraoperatively at the end of CPB in 8 out of 12 patients (66%). Ten patients received VWF/FVIII concentrate intraoperatively as individual treatment attempts during uncontrolled bleeding. They tolerated it well without intraoperative thrombotic events. One patient suffered a transient postoperative cerebral sinuous vein thrombosis. Conclusions: aVWS is of underestimated incidence in complex CHD surgery. These data may offer a new approach to reduce the risk of severe bleedings and to achieve hemostasis during high-risk pedi
Introduction
Acquired von Willebrand syndrome (aVWS) is a bleeding diathesis with heterogeneous etiology, characterized by the decrease or loss of high-molecular-weight von Willebrand factor multimers (HMWM). In patients with cardiovascular disease it is caused by increased formation and subsequent proteolytic clearance of HMWM due to shear stress in the circulation (e.g. on sites of valve stenosis) [1, 2] . Loeffelbein et al. showed some evidence of a positive correlation between the severity of stenosis and the severity of HMWM decrease [3] . In the context of congenital heart disease (CHD) aVWS has previously been reported to be associated with shear stress caused by patent arterial ducts (PDA) [4] , ventricular septal defects [5] and aortic or pulmonary valve stenosis [6] . The aVWS often remains unrecognized because bleeding complications are quite rare in everyday life. However, under conditions of major trauma or surgery aVWS becomes relevant and can be the reason for extensive bleeding [7] . To the best of our knowledge, no data on the incidence of intraoperative aVWS in pediatric patients with complex CHD have been reported so far. The finding that patients with severe stenosis require significantly higher quantities of red packed blood cells units (RBC) and fibrinogen concentrate intraoperatively as compared to patients with mild stenosis [3] indicates that aVWS might contribute to the development of intraoperative bleeding. In adults, lower perioperative von Willebrand factor antigen (VWF:Ag) and VWF collagen binding capacity (VWF:CB) correlated with higher postoperative blood loss [8] , confirming the important role of von Willebrand factor (VWF) in the primary hemostasis following cardiopulmonary bypass (CPB). The role of CPB itself for the development of aVWS in pediatric patients is unclear, although there is considerable evidence that other extracorporeal circuits (e.g. extracorporeal circulation support (ECLS) and ventricular assist devices) trigger the development of aVWS [9, 10] . By contrast, recent data in adults showed that CPB does not induce aVWS [11] . Testing for von Willebrand syndrome (VWS) is complicated because no point-of-care-testing (POCT) method for detection of (a)VWS exists so far. The reference standard for diagnosing aVWS is the time-consuming VWF multimer analysis. Impaired VWF functional markers, such as ratio of ristocetin cofactor activity VWF:RCo/ VWF:Ag < 0.7 or collagen binding VWF:CB/VWF: Ag < 0.7 can sometimes be an indicator of aVWS. However, this is not a reliable diagnostic tool [12] .
Because cardiac surgery on CPB in neonates and infants with complex CHD is almost inevitably associated with bleeding complications, we investigated the incidence of pre-and intraoperative aVWS. In addition, we report on our experience with the intraoperative administration of VWF concentrate in high-risk neonatal cardiac surgery.
Methods

Study design and setting
We performed a single-center, observational analysis regarding the clinical and laboratory manifestation of aVWS in newborns and infants with complex CHD, who underwent a cardiac surgery on cardiopulmonary bypass in our tertiary referral center from September 2015 to April 2016. The study protocol was approved by the institutional research ethics committee of the University of T€ ubingen (468/2016BO2).
Patient selection and data collection
Inclusion criteria were age 0-12 months and diagnosis of complex CHD (e.g. univentricular heart physiology, transposition of the great arteries, etc.) with requirement of corrective or palliative cardiac surgery on CPB (e.g. Norwood procedure, arterial switch operation, etc.), as well as the availability of perioperative VWF parameters. Pre-and intraoperative measurements of VWF parameters were conducted on a routine basis as a part of perioperative coagulation monitoring and management of such patients with a high risk of bleeding.
Exclusion criteria were the lack of perioperative VWF parameters, age > 12 months and cardiac surgery without CPB or for 'simple' CHD with lower risk of perioperative bleeding complications (e.g. atrioventricular septum defect, tetralogy of Fallot, aortic isthmus stenosis, etc.). For such patients, usually no perioperative screening for aVWS was performed.
Clinical decisions on administration of blood components were made at the discretion of attending anesthetists according to the institutional and procedure-related standards. The intraoperative coagulation therapy followed a ROTEM Ò -based (TEM International GmbH, Basel, Switzerland) algorithm for all patients; heparin antagonization after CPB was controlled via the Hepcon Ò -analyzer (Medtronic Inc., Minneapolis, MN, USA). Antifibrinolytic treatment with tranexamic acid was given to all patients during surgery. Intraoperative bleeding was quantified indirectly by comparison of substituted blood components as well as by comparison of the chest closure times (defined as the time from protamine administration until the end of the surgery).
Echocardiographic findings were assessed by pediatric cardiologists. Pressure gradients were determined by Doppler echocardiography and represent the highest systolic peak instantaneous gradient at any localization. Pressure gradients > 50 mmHg were graded as high.
The data including echocardiography findings, laboratory results and data on blood component therapy, as well as bleeding and thrombotic events, were collected retrospectively based on the medical charts.
Laboratory analysis
Blood samples were taken prior to surgery as well as intraoperatively after discontinuation of CPB and administration of protamine. This second blood sample was drawn before administration of fresh frozen plasma (FFP) or any other VWF-containing components. At this stage of surgery usually the establishment of surgical and anesthesiological hemostasis begins. In cases No. 6 and 10 the second blood sample was obtained before the administration of protamine.
Analyses of von Willebrand parameters (VWF:Ag, VWF:CB, VWF:RCo) and factor VIII activity (FVIII: C) were performed as described previously [13] . Plasma samples for multimer analysis were stored frozen at À74°C. SDS electrophoresis for VWF multimer analysis was performed at an external reference laboratory (cMEDILYS Coagulation Laboratory mbH, Asklepios Clinic, Hamburg, Germany) using densitometric gel analysis. Technical details and the methodology of multimer analysis have already been described before [14] .
The aVWS was graded as severe (++) if either a complete loss of the largest multimers was present or if the high molecular multimers were less than 20% of all multimers. Moderate aVWS (+) was defined as a relative loss of the high molecular multimers resulting in a disproportion between the high and low molecular multimers.
Statistical analysis
The statistical analysis and the creation of figures were performed using GraphPad Prism 6 (Version 6.05 for Windows, GraphPad Software, Inc., San Diego, CA, USA). Continuous data are expressed as median and range. The distributions of measurements are shown as box-and-whisker plots. The boundary of the box closest to zero indicates the 25th percentile, a line within the box marks the median, and the boundary of the box farthest from zero indicates the 75th percentile. Whiskers (error bars) above and below the box indicate the 90th and 10th percentiles. Variables were analyzed with regard to significant differences by the Mann-Whitney U-test. A probability of P < 0.05 was defined as statistically significant. Correlations were tested by means of linear regression analysis.
Results
Patient characteristics
Twelve patients aged 0-12 months, requiring complex cardiac surgery for CHD, were included in the analysis. The patients' characteristics, including the diagnoses, the surgical procedures and the maximum echocardiographic pressure gradients before and after surgery are summarized in Table 1 . Eight patients underwent corrective cardiac surgery; four patients with functional univentricular hearts received palliative surgery. The median patient age was 16 (7-186) days (nine neonates and three infants); the median weight was 3.2 (2.7-9.8) kg.
Mean CPB duration was 159 (64-237) min; mean aortic cross-clamp duration was 101 (13-174) min; mean minimal temperature was 28°C (25-35°C).
VWF parameters and FVIII levels
The preoperative values of VWF:Ag, VWF:CB, VWF: RCo and FVIII:C were within the normal range in all patients (Table S1) . A significant increase of VWF:Ag and VWF:CB compared to preoperative values was observed after discontinuation of CPB in most patients (Fig. 1) . VWF:RCo levels and FVIII:C levels also increased after CPB in most patients, but this effect was not as pronounced and was not statistically significant.
Interestingly, the VWF:CB/VWF:Ag ratio was normal (> 0.7) in all patients and did not change significantly during the surgical intervention. In contrast, a low VWF: RCo/VWF:Ag (< 0.7) ratio was detected in three patients (Nos 5, 8 and 11) preoperatively and in four of the patients (Nos 3, 4, 9 and 11) intraoperatively (Fig. 2) . In our cohort of patients the specificity and the positive predictive value (PPV) of the VWF:RCo/VWF:Ag ratio in the aVWS-positive patients was very high (specificity, 1 [95% CI 0.60-1]; PPV, 1 [95% CI 0.64-1]). However, the VWF:RCo/VWF:Ag ratio showed a low sensitivity of 0.38 (95% CI, 0.20-0.61) in predicting aVWS. Moreover, the VWF:RCo/VWF:Ag ratio was significantly associated with the observed HMWM ratio, demonstrating its role in predicting aVWS (Fig. 3) .
Incidence of aVWS by multimer analysis
In the preoperative analysis, 10 of the 12 patients (83%) were diagnosed with aVWS by multimer analysis; four of them (33%) exhibited severe aVWS. Preoperative echocardiographic gradients > 50 mmHg always resulted in aVWS (three patients with severe and one patient with moderate aVWS). All of the aVWS-positive patients had either relevant arterial stenosis (two patients), a PDA (six patients), a VSD (one patient) or a modified Blalock-Taussig-Shunt (BTS) (one patient) as possible sources of turbulent blood flow. Remarkably, only two patients were tested negative for aVWS before operation, both of them with PDA.
Regarding the intraoperative results, eight of 12 patients (66%) had aVWS after discontinuation of CPB. Three of them presented with severe aVWS and five with moderate aVWS. In four patients no aVWS was detected intraoperatively. Intraoperative aVWS was mostly associated with residual systolic gradients or with requirement for ECLS support. Residual systolic gradients were usually due to acceleration of blood flow to the pulmonary artery branches (No. 1), across a VSD (No. 2), or to the aortic valve (No. 3), a prosthetic ventricle-to-pulmonary artery conduit (No. 4), a PDA (No.12) and a BTS (No. 11).
All types of pre-to-post constellations were identifiable in the analyzed patient group. An aVWS was present in seven patients both pre-and intraoperatively (58%). Three patients lost the aVWS and one patient developed aVWS after finishing the surgical procedure. Only one patient (No. 7) was not affected by aVWS at any time, whereas 11 patients (91%) had evidence of aVWS at least at one perioperative time-point. An example of the preand post-CPB multimer analysis of a patient (No. 9) is shown on Fig. 4 .
Clinical parameters
The intraoperatively aVWS-positive and aVWS-negative patients did not differ in the duration of CPB, aortic cross-clamp time or the degree of intraoperative hypothermia. Also, no difference in the transfused volumes of RBC, FFP and platelets (PLT) could be detected between the two groups. All patients experienced significant bleeding and had long chest closure times (77-271 min). The administration of diverse procoagulant factor concentrates was also necessary. For more detailed information on transfused blood components see Table S2 .
We decided to administer VWF/FVIII concentrate to the patients who had severe intraoperative bleeding on the basis of individual treatment attempts. Ten patients (No. 1-10) received VWF/FVIII concentrate intraoperatively. It was given fractionated in cumulative doses ranging from 45 to 390 IU/kgBW À1 (mean 133 AE 107 IU/ kgBW À1 ).
We did not find a significant relationship between the dose of VWF/FVIII concentrate administered and the chest closure times, the drainage blood loss within the first 24 h postoperatively or the other substituted blood components. VWF/FVIII concentrate was tolerated well by the patients. There were no thromboembolic complications during the intra-and postoperative period, except for one patient (No. 7) who suffered a postoperative transient cerebral venous sinus thrombosis (CSVT) detected on a routine cerebral ultrasound 4 h after surgery. After a therapeutic anticoagulation with unfractioned heparin it resolved on the first postoperative day. However, the patient was also exposed to recombinant factor VIIa (rFVIIa) intraoperatively, which most likely caused the thrombotic event.
Discussion
Our data show that perioperative aVWS is a more common condition in neonates and infants with complex CHD than until now assumed. Important reasons for underdiagnosing are the lack of opportunities for rapid testing and the uncommonness of this coagulopathy in adults after CPB surgery [15] . The finding is also in contrast to the coagulation status of healthy neonates, who have significantly increased VWF function and HMWM fraction as compared with adults [16] .
In the preoperative screening, echocardiographic gradients > 50 mmHg were always associated with aVWS, but it could also be observed in patients with lower gradients bearing anatomic features like mild stenosis, VSD, PDA or BTS. Hypothetically it is possible that not only unphysiologic acceleration of blood flow across a stenosis, but also abnormal turbulent flow (e.g. across a nonrestrictive VSD or an elongated PDA), might cause increased shear stress and result in aVWS. On the other hand, the simple presence of a PDA is strongly, but not inevitably associated with aVWS, as previously reported [4] . In our cohort there were two patients with transposition of the great arteries and PDA who had a normal preoperative multimer pattern. These findings indicate that, depending on the velocity and turbulence of flow across the PDA, it might take a variably long period of time to develop the aVWS. Thus, it is possible that neonates with 'low shear stress' PDA characterized by low flow velocities in the presence of high pulmonary vascular resistance have a normal multimer pattern within the first weeks of life.
With respect to the intraoperative incidence of aVWS, this is the first report in the literature describing the testing of pediatric patients immediately after discontinuation of CPB. In 1992 Turner-Gomes et al. already described a markedly increased biologic activity of von Willebrand factor after CPB in children [17] , but multimer analysis was not performed in their cohort. In accordance with the findings in adults undergoing cardiac surgery under CPB [11, 15, 18] , the neonates and infants also showed an increase in the absolute values of VWF:Ag, VWF:CB, VWF:RCo and FVIII:C after discontinuation of CPB compared with their preoperative values. This increase is probably a result of VWF release from activated platelets and endothelial cells under CPB conditions, but it does not necessarily reflect the multimer function. The intraoperative incidence of aVWS in infants and neonates with complex CHD was still quite significant and constituted 66%. One possible explanation for this finding is that the postoperative hemodynamics in many infants with CHD still may be associated with areas of turbulent or accelerated blood flow such as residual stenosis or palliative constructed shunts, representing potential sites of HMWM consumption. There was one patient (No. 9) who underwent complete repair of his cardiac defect without residual stenosis after surgery but still manifested with a severe aVWS intraoperatively. This case indicates that there must be other causes for intraoperative aVWS, including possibly the CPB itself. Because aortic cannulas in children have a very low internal diameter (6) (7) (8) , high velocities and shear stress at the top of the cannula may result in increased HMWM consumption. Three patients recovered from aVWS intraoperatively. It seems as though the elimination of the shear stress source by repair of the heart defect has led to an immediate normalization of their multimer pattern just after CPB discontinuation. Nevertheless, it is unclear if there are also other determining factors such as a different individual multimer recovery capacity or CPB-dependent variables.
Concerning the detection of aVWS, our data underline the importance of multimer analysis as the only reliable diagnostic tool. Unfortunately, it is unsuited for rapid clinical diagnosis and treatment of aVWS. In our cohort of patients the diagnostic sensitivity of the VWF:CB/ VWF:Ag ratio (< 0.7) was not useful in predicting aVWS. This in contrast to data presented in 192 adults with a congenital heart disease, where VWF:CB/VWF:Ag ratios showed a sensitivity of 0.78 [19] . According to our results, a decreased ratio of VWF:RCo/VWF:Ag < 0.7 showed a high specificity (100%) and might serve as an indicator of aVWS. It can be used in clinical practice if the local laboratory is able to provide these measurements in a timely manner. However, the low sensitivity of this parameter (36%) would frequently lead to underdiagnosing of the condition.
Even the combination of VWF: Ag < 50 IU dL À1 , VWF:RCo/VWF:AG ratio < 0.7 and VWF:CB/VWF:Ag < 0.8, in which a sensitivity of 0.86 has been reported [20] , failed in our patients. The different sensitivities observed here might be explained by the fact that mainly the thrombocyte-VWF interaction is affected in aVWS and VWF:RCo-activity is a marker for VWF binding capacity to platelets [7] . Previous findings of significantly decreased VWF:RCo/VWF:Ag ratios in patients with aVWS on ECLS support [10] analogically led the authors to the conclusion that the VWF:RCo/ VWF:Ag ratio might be of relevance as an early diagnostic marker.
Recently, aVWS has been described as a relevant cause of major bleeding in the cardiac intensive care unit [21] , but the impact of aVWS on the intraoperative bleeding tendency of infants with complex CHD is still unclear, because of the abundance of other potential causes for intraoperative hemorrhage. Neonates and infants undergoing complex cardiac surgery are most challenging in terms of intraoperative coagulation management as they tend to develop intense and profound bleeding episodes, often requiring massive transfusions [22] . This fact is illustrated by the data from our cohort. The use of procoagulant products in the described patient series was very high despite the ROTEM-guided coagulation management. The reasons for this are certainly heterogeneous and comprise some surgical complications as well as treatment attempts with coagulation factor concentrates on the discretion of the attending anesthetists when patients had uncontrolled bleeding.
Because aVWS is a condition caused by deficiency of HMWM, the administration of concentrates containing high quantities of the hemostatically active HMWM should be the most effective and specific treatment to provide the best protection against intraoperative bleeding associated with aVWS [7, 12] . Desmopressin (DDAVP) is not that effective in aVWS because of the patients' high amount of circulating VWF with compromised function [12] and it does not reduce bleeding or transfusion requirements in congenital heart operations [23] . To the best of our knowledge, there are no reports describing the intraoperative use of VWF/FVIII concentrate so far. The patients who received VWF/FVIII concentrate intraoperatively tolerated it well and no intraoperative adverse events occurred in association with its use. A postoperative transient CSVT was diagnosed in one case, but this patient also received rFVIIa, which is a known thrombogenic agent associated with increased mortality after cardiac surgery [24, 25] . Neonates and infants with CHD are generally at increased risk of thromboembolic complications because of a CHD-associated imbalance between pro-and antithrombotic activity, abnormally low blood flow velocities and prothrombotic foreign materials [26] [27] [28] [29] [30] [31] . Hunt et al. described a functional imbalance between VWF and ADAMTS-13 in the perioperative period for neonates and infants with CHD, which also might contribute to thrombotic events because of lower postoperative levels of ADAMTS-13 [32] . For this reason, supplementation with VWF concentrate bears a potential risk of thrombosis and should also be considered carefully.
Our study has several limitations. Because of its singlecenter design and broad exclusion criteria only a small number of patients with the most complex cardiac defects were included in the analysis. It was not possible to identify a control group because of the lack of routine VWF data for patients with lower intraoperative bleeding risk and shorter operation times. For this reason, the patients described in this manuscript are not representative of the whole cohort of neonates and infants with CHD requiring cardiac surgery. The consecutiveness of the included patients could also not be guaranteed by prospective screening, but as far as we could see from the medical charts, all patients undergoing complex cardiac surgery were monitored for aVWS perioperatively. Statistical differences reported in the manuscript should be interpreted with caution, because the small numbers make a type I statistical error more likely.
In summary, the exact impact of aVWS on intraoperative bleeding remains unclear. At this stage we can only hypothesize on the importance of an intact function and quantity of VWF and its HMWM for achievement of rapid hemostasis under conditions of highly invasive surgery. The intraoperative administration of VWF concentrate was well tolerated and did not lead to increased thromboembolic events in the small cohort. Nevertheless, in order to minimize the risk of thromboembolic complications it is essential to identify the patients with intraoperative aVWS in a timely manner. Currently, this is only possible by using the VWF:RCo/VWF:Ag ratio and being aware of its low sensitivity.
Another way to approach this problem is to carry out further prospective studies on larger cohorts to elucidate the factors involved in the pathogenesis of intraoperative aVWS and to define the patients who will benefit from intraoperative VWF/FVIII concentrate substitution. Budde also interpreted multimer analysis data. All authors revised the manuscript for important intellectual content. All authors read and approved the final manuscript.
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